Endologix (ELGX) Getting Somewhat Favorable Press Coverage, Accern Reports

News articles about Endologix (NASDAQ:ELGX) have been trending somewhat positive recently, Accern reports. The research firm identifies negative and positive news coverage by monitoring more than 20 million news and blog sources in real-time. Accern ranks coverage of companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Endologix earned a daily sentiment score of 0.18 on Accern’s scale. Accern also assigned media coverage about the medical instruments supplier an impact score of 47.3274194869717 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the stock’s share price in the near term.

A number of equities analysts have commented on the stock. Piper Jaffray Companies reissued an “overweight” rating on shares of Endologix in a research note on Tuesday, December 12th. Royal Bank of Canada cut their price target on shares of Endologix from $5.00 to $4.00 and set a “sector perform” rating for the company in a research note on Wednesday, November 8th. Canaccord Genuity reissued a “hold” rating and issued a $5.00 price target on shares of Endologix in a research note on Monday, October 9th. Stifel Nicolaus set a $6.00 price target on shares of Endologix and gave the stock a “hold” rating in a research note on Friday, October 6th. Finally, JPMorgan Chase & Co. cut shares of Endologix from a “neutral” rating to an “underweight” rating in a research note on Tuesday, January 2nd. Two equities research analysts have rated the stock with a sell rating, nine have given a hold rating and one has assigned a buy rating to the stock. The stock currently has an average rating of “Hold” and an average price target of $5.41.

Endologix (ELGX) opened at $4.24 on Thursday. The company has a quick ratio of 2.11, a current ratio of 2.90 and a debt-to-equity ratio of 2.61. Endologix has a 12 month low of $4.08 and a 12 month high of $7.66. The company has a market cap of $354.68, a P/E ratio of -4.56 and a beta of 0.72.

Endologix (NASDAQ:ELGX) last released its quarterly earnings results on Tuesday, November 7th. The medical instruments supplier reported ($0.11) EPS for the quarter, topping the Zacks’ consensus estimate of ($0.17) by $0.06. Endologix had a negative net margin of 41.60% and a negative return on equity of 52.18%. sell-side analysts expect that Endologix will post -0.68 earnings per share for the current year.

ILLEGAL ACTIVITY WARNING: “Endologix (ELGX) Getting Somewhat Favorable Press Coverage, Accern Reports” was originally reported by Community Financial News and is the sole property of of Community Financial News. If you are viewing this piece on another site, it was copied illegally and reposted in violation of US & international trademark and copyright legislation. The legal version of this piece can be read at https://www.com-unik.info/2018/01/18/endologix-elgx-getting-somewhat-favorable-press-coverage-accern-reports.html.

About Endologix

Endologix, Inc is engaged in developing, manufacturing, marketing and selling medical devices for the treatment of aortic disorders. The Company’s products are intended for the treatment of abdominal aortic aneurysms (AAA). The AAA products are built on one of two platforms, including traditional minimally invasive endovascular repair (EVAR) or endovascular sealing (EVAS), its solution for sealing the aneurysm sac while maintaining blood flow through two blood flow lumens.

Insider Buying and Selling by Quarter for Endologix (NASDAQ:ELGX)

Receive News & Ratings for Endologix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Endologix and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit